Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer

Phase 2

Completed

• Conditions: Prostate Cancer
• Interventions: Radiation: High Dose brachytherapy boost; Radiation: External beam radiotherapy

• Registration Number: NCT00091390
• Lead Sponsor: Radiation Therapy Oncology Group

Brief Summary

RATIONALE: Radiation therapy uses high-energy x-rays and other sources to damage tumor cells. Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Giving radiation therapy in different ways may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving internal radiation therapy together with external-beam radiation therapy works in treating patients with stage II or stage III prostate cancer.

Detailed Description

OBJECTIVES:

Primary

* Determine the rate of late grade 3 or greater genitourinary and gastrointestinal toxicity after treatment with external beam radiotherapy and high-dose rate brachytherapy in patients with stage II or III adenocarcinoma of the prostate.

Secondary

* Determine acute grade 3 or greater genitourinary and gastrointestinal toxicity in patients treated with this regimen.

* Determine freedom from biochemical failure in patients treated with this regimen.

* Determine overall survival of patients treated with this regimen.

* Determine disease-specific survival of patients treated with this regimen.

* Determine clinical relapse (local and/or distant) in patients treated with this regimen.

* Develop a quality assurance process for high-dose rate prostate brachytherapy.

OUTLINE: This is a multicenter study. Patients are stratified according to prostate-specific antigen (≤ 10 ng/mL vs 11-20 ng/mL), T stage (T1c-T2c vs T3a-T3b), combined Gleason score (2-6 vs 7 vs 8-10), prior hormonal therapy (no vs yes), and timing of high-dose rate brachytherapy (before external beam radiotherapy vs after external beam radiotherapy).

Patients are followed at 3, 7, 9, and 12 months, every 6 months for 5 years, and then annually thereafter.

Study Timeline

• Study Start: 2004-07
• Study First Submitted: 2004-09-07
• Study First Submitted QC: 2004-09-08
• Study First Posted: 2004-09-09
• Primary Completion: 2008-01
• Results First Submitted: 2014-10-31
• Results First Submitted QC: 2014-10-31
• Results First Posted: 2014-11-14
• Study Completion: 2016-12
• Status Verified: 2020-07
• Last Update Submitted: 2020-07-28
• Last Update Posted: 2020-08-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 129

Inclusion Criteria

1. Histologically confirmed, adenocarcinoma of the prostate, clinical stage T1c-T3b, N0, M0.

2. Patient will have clinically negative nodes as established by imaging (pelvic computed tomography (CT), magnetic resonance imaging (MRI)).

3. The patient will be clinically M0.

4. Zubrod status 0-1.

5. No prior pelvic or prostate radiation or chemotherapy for prostate cancer; induction hormonal therapy beginning ≤ 120 days prior to registration is acceptable.

6. One of the following combinations of factors:

   Clinical stage T1c-T2c, Gleason score 2-6 and prostate-specific antigen (PSA) >10 but ≤ 20 Clinical stage T3a-T3b, Gleason score 2-6 and PSA ≤ 20 Clinical stage T1c-T3b, Gleason score 7-10 and PSA ≤ 20

7. Patients must sign a study-specific consent form prior to registration.

Exclusion Criteria

1. Stage T4 disease.
2. Lymph node involvement (N1).
3. Evidence of distant metastases (M1).
4. Radical surgery for carcinoma of the prostate.
5. Previous hormonal therapy beginning > 120 days prior to registration.
6. Major medical or psychiatric illness which, in the investigator's opinion, would prevent completion of treatment and would interfere with follow-up.
7. Prior transurethral resection of the prostate (TURP).
8. Prior invasive malignancy(except non-melanomatous skin cancer) unless disease free for a minimum of 3 years (For example, carcinoma in situ of the oral cavity or bladder are permissible).
9. Hip prosthesis.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
External Beam Radiotherapy and High Dose brachytherapy boost	High Dose brachytherapy boost	-
External Beam Radiotherapy and High Dose brachytherapy boost	External beam radiotherapy	-

Primary Outcome Measures

Name	Time	Method
Percentage of Participants With Late Grade 3-5 Genitourinary (GU) and Gastrointestinal (GI) Adverse Events (AE) at 18 Months	From 9 to 18 months after start of study treatment	Adverse events (AE) were graded using the Common Terminology Criteria for Adverse Events (CTCAE) v3.0. Grade refers to the severity of the AE. The CTCAE v3.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild, Grade 2 Moderate, Grade 3 Severe, Grade 4 Life-threatening or disabling, Grade 5 Death related to AE. "Late" is defined as occurring after 9 months from the start of study treatment. Because of the lead time of 9 months, the percentage at 18-months was estimated by the 9-month rate using the cumulative incidence method starting at the 10th month. Death was treated as a competing risk.

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants Alive at 10 Years	From registration to 10 years	Overall survival time is defined as time from registration to the date of death from any cause or last known follow-up (censored). Overall survival rate is estimated by the Kaplan-Meier method.
Percentage of Participants With Distant Failure at 10 Years	From registration to ten years	Distant failure required documentation of regional nodal recurrence or distant disease relapse. Time to failure is defined as time from registration to the date of first failure, last known follow-up (censored), or death without failure (competing risk). Failure rate is estimated using the cumulative incidence method.
Number of Participants With Acute Grade 3-5 Genitourinary (GU) and Gastrointestinal (GI) Adverse Events (AE)	From treatment start to 9 months	Adverse events (AE) were graded using the Common Terminology Criteria for Adverse Events (CTCAE) v3.0. Grade refers to the severity of the AE. The CTCAE v3.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild, Grade 2 Moderate, Grade 3 Severe, Grade 4 Life-threatening or disabling, Grade 5 Death related to AE. Acute is defined as occurring within 9 months from the start of study treatment.
Percentage of Participants With Biochemical Failure at 10 Years Using the Phoenix Definition	From registration to ten years	The Phoenix criteria for biochemical failure is a rise of 2 ng/mL or more above the nadir after radiation therapy. Time to failure is defined as time from registration to the date of first failure, last known follow-up (censored), or death without failure (competing risk). Failure rate is estimated using the cumulative incidence method.
Percentage of Participants With Biochemical Failure at 10 Years Using American Society for Therapeutic Radiation and Oncology (ASTRO) Definition	From registration to ten years	The ASTRO criteria for biochemical failure is three consecutive rises in prostate-specific antigen (PSA) level above the nadir after radiation therapy. The PSA nadir is defined as as the lowest PSA value reached immediately before a biochemical failure. The date of failure is midway between the last non-rising PSA and the first rise in PSA. Time to failure is defined as time from registration to the date of first failure, last known follow-up (censored), or death without failure (competing risk). Failure rate is estimated using the cumulative incidence method.
Percentage of Participants With Death Due to Prostate Cancer at 10 Years	From registration to ten years	The following will be considered as death due to prostate cancer (failure): * Death certified as due to prostate cancer.; * Death from other causes with active malignancy (clinical or biochemical progression).; * Death due to complications of treatment, irrespective of the status of malignancy.; Time to failure is defined as time from registration to the date of first failure, last known follow-up (censored), or death without failure (competing risk). Failure rate is estimated using the cumulative incidence method.
Percentage of Participants With Local Failure at 10 Years	From registration to ten years	Local failure is defined as documented local progression as determined by clinical exam. Time to failure is defined as time from registration to the date of first failure, last known follow-up (censored), or death without failure (competing risk). Failure rate is estimated using the cumulative incidence method.

Trial Locations

Locations (12)

Roswell Park Cancer Institute; 🇺🇸 Buffalo, New York, United States

OSF St. Francis Medical Center; 🇺🇸 Peoria, Illinois, United States

Cancer Care Consultants Medical Associates at Daniel Freeman Memorial Hospital; 🇺🇸 Inglewood, California, United States

William Beaumont Hospital - Royal Oak Campus; 🇺🇸 Royal Oak, Michigan, United States

Radiological Associates of Sacramento Medical Group, Incorporated; 🇺🇸 Sacramento, California, United States

Newark Beth Israel Medical Center; 🇺🇸 Newark, New Jersey, United States

Fletcher Allen Health Care - University Health Center Campus; 🇺🇸 Burlington, Vermont, United States

Providence Saint Joseph Medical Center - Burbank; 🇺🇸 Burbank, California, United States

Lynn Regional Cancer Center at Boca Raton Community Hospital - Main Center; 🇺🇸 Boca Raton, Florida, United States

Maine Center for Cancer Medicine and Blood Disorders - Scarborough; 🇺🇸 Scarborough, Maine, United States

Waukesha Memorial Hospital Regional Cancer Center; 🇺🇸 Waukesha, Wisconsin, United States

University of Colorado Cancer Center at University of Colorado Health Sciences Center; 🇺🇸 Aurora, Colorado, United States